Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sikkerhet og effektivitet av venstrebundets grenområde stimulerende kontra konvensjonell hjertesynkroniseringsterapi i hjertesvikt (SYNCHRONICITY)

2. november 2026 oppdatert av: Boston Scientific Corporation

This study will compare two different methods to pace the heart to treat heart failure including:

  1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
  2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

850

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alabama
      • Huntsville, Alabama, Forente stater, 35801
        • Rekruttering
        • Heart Center Research, LLC
        • Ta kontakt med:
          • John Jennings, Dr.
        • Hovedetterforsker:
          • John Jennings, Dr.
      • Mobile, Alabama, Forente stater, 36608
        • Rekruttering
        • Mobile Infirmary Medical Center
        • Ta kontakt med:
          • Ernest Matthew Quin, Dr.
        • Hovedetterforsker:
          • Ernest Matthew Quin, Dr.
    • Arizona
      • Phoenix, Arizona, Forente stater, 85054
        • Rekruttering
        • Mayo Clinic Phoenix
        • Ta kontakt med:
          • Mayank Sardana, MD
        • Hovedetterforsker:
          • Mayank Sardana, MD
    • Arkansas
      • Jonesboro, Arkansas, Forente stater, 72401
        • Rekruttering
        • Arrhythmia Research Group
        • Ta kontakt med:
          • Devi Nair, Dr.
        • Hovedetterforsker:
          • Devi Nair, Dr.
    • California
      • La Jolla, California, Forente stater, 92037
        • Rekruttering
        • Scripps Memorial Hospital
        • Ta kontakt med:
          • Nicolas Olson, MD
        • Hovedetterforsker:
          • Nicolas Olson, MD
      • Los Angeles, California, Forente stater, 90048
        • Rekruttering
        • Cedars Sinai Medical Center
        • Hovedetterforsker:
          • Ashkan Ehdaie, MD
        • Ta kontakt med:
          • Ashkan Ehdaie, MD
      • Oakland, California, Forente stater, 94609
        • Rekruttering
        • Alta Bates Summit Medical Center
        • Ta kontakt med:
          • Rajan Shah, Dr.
        • Hovedetterforsker:
          • Rajan Shah, Dr.
      • Santa Monica, California, Forente stater, 90404
        • Rekruttering
        • Pacific Heart Institute
        • Ta kontakt med:
          • Stephen Tang, MD
        • Hovedetterforsker:
          • Stephan Tang, MD
      • Torrance, California, Forente stater, 90505
        • Rekruttering
        • Torrance Medical Center
        • Hovedetterforsker:
          • Gene Kim, MD
        • Ta kontakt med:
          • Gene Kim, MD
      • Ventura, California, Forente stater, 93003
        • Rekruttering
        • Cardiology Associates Medical Group, Inc.
        • Ta kontakt med:
          • Jonathan Dukes, Dr.
        • Hovedetterforsker:
          • Jonathan Dukes, Dr.
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • Rekruttering
        • Washington Hospital Center
        • Ta kontakt med:
          • Cyrus Hadadi, MD
        • Hovedetterforsker:
          • Cyrus Hadadi, MD
    • Florida
      • Sarasota, Florida, Forente stater, 34239
        • Rekruttering
        • Sarasota Memorial Hospital
        • Ta kontakt med:
          • Antonio Moretta, Dr.
        • Hovedetterforsker:
          • Antonio Moretta, Dr.
      • Tampa, Florida, Forente stater, 33613
        • Rekruttering
        • AdventHealth Tampa
        • Hovedetterforsker:
          • Kenneth Yamamura, MD
        • Ta kontakt med:
          • Kenneth Yamamura, MD
    • Georgia
      • Atlanta, Georgia, Forente stater, 30309
        • Rekruttering
        • Piedmont Hospital
        • Ta kontakt med:
          • Kavita Krishnasamy, MD
        • Hovedetterforsker:
          • Kavita Krishnasamy, MD
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Emory University Hospital
        • Ta kontakt med:
          • Anand Shah, MD
        • Hovedetterforsker:
          • Anand Shah, MD
    • Idaho
      • Meridian, Idaho, Forente stater, 83642
        • Rekruttering
        • St. Luke's Idaho Cardiology Associates
        • Ta kontakt med:
          • Justice Oranefo, MD
        • Hovedetterforsker:
          • Justice Oranefo, MD
    • Illinois
      • Hinsdale, Illinois, Forente stater, 60521
        • Rekruttering
        • University of Chicago
        • Ta kontakt med:
          • Shrinath Yeshwant, MD
        • Hovedetterforsker:
          • Shrinath Yeshwant, MD
      • Naperville, Illinois, Forente stater, 60540
        • Tilbaketrukket
        • Midwest Cardiovascular Institute
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46250
        • Rekruttering
        • Community Heart and Vascular Hospital
        • Ta kontakt med:
          • Krishna Malineni, MD
        • Hovedetterforsker:
          • Krishna Malineni, MD
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Rekruttering
        • University of Iowa Hospitals and Clinics
        • Hovedetterforsker:
          • Paari Dominic, MD
        • Ta kontakt med:
          • Paari Dominic, MD
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40207
        • Rekruttering
        • Baptist Hospital East Louisville
        • Hovedetterforsker:
          • Kevin Parrott, MD
        • Ta kontakt med:
          • Kevin Parrott, MD
    • Massachusetts
      • Fall River, Massachusetts, Forente stater, 02720
        • Rekruttering
        • Southcoast Physicians Group
        • Ta kontakt med:
          • Arnoldas Giedrimas, MD
        • Hovedetterforsker:
          • Arnoldas Giedrimas, MD
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan Hospitals
        • Hovedetterforsker:
          • Thomas Crawford, MD
        • Ta kontakt med:
          • Thomas Crawford, MD
      • Grand Rapids, Michigan, Forente stater, 49525
        • Rekruttering
        • Corewell Health
        • Ta kontakt med:
          • Jawad Wassim, MD
        • Hovedetterforsker:
          • Jawad Wassim, MD
    • Minnesota
      • Duluth, Minnesota, Forente stater, 55805
        • Tilbaketrukket
        • St. Mary's Duluth Clinic Regional Heart Center
      • Saint Cloud, Minnesota, Forente stater, 56303
        • Tilbaketrukket
        • Centracare Heart and Vascular Center
    • New Jersey
      • Morristown, New Jersey, Forente stater, 07932
        • Rekruttering
        • Morristown Medical Center
        • Ta kontakt med:
          • Michael Katz, MD
        • Hovedetterforsker:
          • Michael Katz, MD
    • New York
      • Albany, New York, Forente stater, 12211
        • Rekruttering
        • Capital Cardiology Associates
        • Ta kontakt med:
          • Rizwan Alimohammad, MD
        • Hovedetterforsker:
          • Rizwan Alimohammad, MD
      • Flushing, New York, Forente stater, 11355
        • Rekruttering
        • New York Hospital Queens
        • Ta kontakt med:
          • Seth Goldbarg, Dr.
        • Hovedetterforsker:
          • Seth Goldbarg, Dr.
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Weill Cornell Medical University
        • Ta kontakt med:
          • Jim Cheung, Dr.
        • Hovedetterforsker:
          • Jim Cheung, Dr.
      • New York, New York, Forente stater, 14621
        • Rekruttering
        • Rochester General Hospital
        • Ta kontakt med:
          • Dmitry Chuprun, MD
        • Hovedetterforsker:
          • Dmitry Chuprun, MD
      • Syracuse, New York, Forente stater, 13057
        • Rekruttering
        • SUNY-Upstate Medical University
        • Ta kontakt med:
          • Jorge Romero, MD
        • Hovedetterforsker:
          • Jorge Romero, MD
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28204
        • Rekruttering
        • Sanger Heart and Vascular Institute
        • Ta kontakt med:
          • Navid Nafissi, MD
        • Hovedetterforsker:
          • Navid Nafissi, MD
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Ta kontakt med:
          • Daniel Friedman, MD
        • Hovedetterforsker:
          • Daniel Friedman, MD
    • Ohio
      • Columbus, Ohio, Forente stater, 43219
        • Rekruttering
        • Mount Carmel Health System
        • Ta kontakt med:
          • Kamel Addo, MD
        • Hovedetterforsker:
          • Kamel Addo, MD
      • Columbus, Ohio, Forente stater, 43214
        • Rekruttering
        • OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
        • Ta kontakt med:
          • Anish Amin, MD
        • Hovedetterforsker:
          • Anish Amin, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Penn Presbyterian Medical Center
        • Ta kontakt med:
          • John Bullinga, MD
        • Hovedetterforsker:
          • John Bullinga, MD
      • Wilkes-Barre, Pennsylvania, Forente stater, 18702
        • Rekruttering
        • Geisinger Wyoming Valley
        • Hovedetterforsker:
          • Pugazhendhi Vijayaraman, MD
        • Ta kontakt med:
          • Pugazhendhi Vijayaraman, MD
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57108
        • Rekruttering
        • Avera Heart Hospital of South Dakota
        • Ta kontakt med:
          • Christopher Stanton, Dr.
        • Hovedetterforsker:
          • Christopher Stanton, Dr.
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37205
        • Rekruttering
        • St.Thomas Health
        • Ta kontakt med:
          • Ricardo Lugo, MD
        • Hovedetterforsker:
          • Ricardo Lugo, MD
    • Texas
      • Plano, Texas, Forente stater, 75093
        • Rekruttering
        • Heart Hospital Baylor Plano
        • Ta kontakt med:
          • Mustafa Dohadwala, MD
        • Hovedetterforsker:
          • Mustafa Dohadwala, MD
      • Tyler, Texas, Forente stater, 75701
        • Rekruttering
        • Christus Trinity Mother Frances Health System
        • Ta kontakt med:
          • Stanislov Weiner, Dr.
        • Hovedetterforsker:
          • Stanislov Weiner, Dr.
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • Rekruttering
        • University of Virginia Medical Center
        • Hovedetterforsker:
          • Pamela Mason, MD
        • Ta kontakt med:
          • Pamela Mason, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law

  2. Patient meets a guideline-based indication for a de novo CRT-D device

  3. Primary prevention indication for ICD therapy

  4. Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)

  5. NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months

    *GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications

  6. Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment

  7. Patient is willing to participate in LATITUDE™ NXT remote patient monitoring

  8. Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)

  9. Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)

Exclusion Criteria:

  1. Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
  2. Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
  3. Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
  4. Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
  5. Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
  6. Prior or planned mechanical or bioprosthetic tricuspid valve replacement
  7. Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
  8. Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
  9. History of heart transplantation or left ventricular assist device (LVAD) implantation
  10. Less than 1 year of life expectancy at the time of enrollment
  11. Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
  12. History of ventricular septal defect (VSD)
  13. Complex congenital heart disease
  14. Documented diagnosis of cardiac amyloidosis
  15. Known occlusion or other reason limiting central venous access for transvenous leads
  16. Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
  17. Patient currently requiring dialysis
  18. Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
  19. Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
  20. Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
  21. Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: CRT Cohort

Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.

Eksperimentell: LBBA Cohort

Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to maximum of 5 years
System-related complication-free rate
Tidsramme: 12 months

The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal

12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Win ratio composite assessment
Tidsramme: Through study completion, up to a maximum of 5 years

Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life

Through study completion, up to a maximum of 5 years
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to a maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to a maximum of 5 years
System-related complication-free rate between randomized arms
Tidsramme: 12 months

System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms.

12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. oktober 2025

Primær fullføring (Antatt)

1. november 2029

Studiet fullført (Antatt)

1. november 2029

Datoer for studieregistrering

Først innsendt

23. juni 2025

Først innsendt som oppfylte QC-kriteriene

7. juli 2025

Først lagt ut (Faktiske)

17. juli 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • C2403

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .